MUNICH and LISBON, Portugal (ots) – New information on cystic fibrosis (CF) was presented at the 36th European Cystic Fibrosis Society (ECFS) Conference from 12-15 June in Lisbon.
At the symposium hosted by PARI GmbH, Prof. Niels Høiby of Copenhagen University Hospital, Prof. Felix Ratjen of the University Hospital of Toronto and PD Dr. Jochen Mainz of Jena University Hospital discussed strategies for treating the upper airways to reduce the risk of lung infections in CF patients.
Around 65% of CF patients have intermittent or chronic rhinosinusitis (CRS). “CF patients have a genetic defect that also affects the upper airways,” stated Dr. Mainz. “The environment is ideal for microorganisms, as the mucociliary clearance does not work properly.”
The Copenhagen team under Prof. Høiby supports the concept of “One Airway-One Disease?: the upper and lower airways form an anatomical continuum that is also relevant for microorganisms and inflammatory mediators. In CF patients, the upper airways act like a reservoir for bacteria, which can then spread from there into the lungs. The genotypes of microorganisms in the upper and lower airways are invariably identical, confirmed Dr. Mainz from Jena . He described transplanted CF patients in whom genotypically identical Pseudomonas aeruginosa persisted in the nasopharyngeal cavity after LTX and from there infected the new lungs .
In Jena, the upper airways of CF patients are therefore being systematically investigated for typical CF microbes . The aim, as far as possible, is to use conservative means to prevent the development of CRS and avoid the need for sinonasal surgery. According to Dr. Mainz “the recurrence rate for sinonasal surgery is high and the function of the nasal conchae can be impaired”.
The PARI SINUS inhalation device is particularly suited as a conservative therapy. It produces a pulsating aerosol and, by creating differences in pressure, promotes ventilation of the paranasal sinuses. In contrast to nasal sprays, the pulsating aerosol actually reaches the paranasal sinuses and demonstrates a longer retention time . The data Dr. Mainz presented referred to the use of tobramycin , dornase alfa  or salt solutions (0.9%, 6.0%), CF-specific drugs, which can be nebulised with the PARI SINUS.
Pilot studies have confirmed the efficacy of the PARI SINUS in improving the quality of life of CF patients. An ongoing multi-centre, placebo-controlled study shows promising results.
Petra Kaden Tel. +49(0)8151-279-119